Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Number of holders
-
171
-
Total 13F shares, excl. options
-
78,904,235
-
Shares change
-
+3,041,858
-
Total reported value, excl. options
-
$571,951,639
-
Value change
-
+$12,362,063
-
Put/Call ratio
-
6.2%
-
Number of buys
-
91
-
Number of sells
-
-74
-
Price
-
$7.24
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q2 2022
197 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q2 2022.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 171 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78,904,235 shares
of 116,964,738 outstanding shares and own 67% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12,883,490 shares), Temasek Holdings (Private) Ltd (7,381,116 shares), JPMORGAN CHASE & CO (6,486,231 shares), STATE STREET CORP (6,383,103 shares), ALLIANCEBERNSTEIN L.P. (5,675,449 shares), VANGUARD GROUP INC (4,883,415 shares), PERCEPTIVE ADVISORS LLC (3,645,471 shares), Kohlberg Kravis Roberts & Co. L.P. (3,036,076 shares), Aristotle Capital Boston, LLC (2,322,168 shares), and AMERIPRISE FINANCIAL INC (1,944,003 shares).
This table shows the top 171 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.